Advisor Group Holdings Inc. Boosts Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

Advisor Group Holdings Inc. lifted its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) by 16.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,196 shares of the company’s stock after buying an additional 2,569 shares during the quarter. Advisor Group Holdings Inc.’s holdings in Bicycle Therapeutics were worth $552,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new stake in shares of Bicycle Therapeutics during the first quarter worth about $39,000. Personal CFO Solutions LLC purchased a new stake in Bicycle Therapeutics in the second quarter valued at approximately $221,000. Glenmede Trust Co. NA acquired a new position in Bicycle Therapeutics during the first quarter valued at approximately $295,000. Schonfeld Strategic Advisors LLC acquired a new position in Bicycle Therapeutics during the first quarter valued at approximately $331,000. Finally, Barclays PLC acquired a new position in Bicycle Therapeutics during the first quarter valued at approximately $612,000. Institutional investors and hedge funds own 48.67% of the company’s stock.

BCYC has been the topic of a number of recent research reports. JMP Securities reaffirmed a “buy” rating and set a $53.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, August 11th. Piper Sandler lifted their price target on shares of Bicycle Therapeutics from $39.00 to $46.00 and gave the company an “overweight” rating in a research report on Tuesday, July 13th. Zacks Investment Research cut shares of Bicycle Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 6th. Finally, Canaccord Genuity boosted their target price on shares of Bicycle Therapeutics from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $44.43.

BCYC opened at $42.02 on Tuesday. The stock has a market capitalization of $1.07 billion, a PE ratio of -15.49 and a beta of -0.34. The firm’s fifty day moving average price is $34.22 and its 200 day moving average price is $31.13. The company has a debt-to-equity ratio of 0.21, a current ratio of 9.36 and a quick ratio of 9.36. Bicycle Therapeutics plc has a 12-month low of $17.68 and a 12-month high of $45.21.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, August 5th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.03). The company had revenue of $1.79 million during the quarter, compared to analyst estimates of $2.51 million. Bicycle Therapeutics had a negative net margin of 546.62% and a negative return on equity of 50.43%. On average, equities research analysts forecast that Bicycle Therapeutics plc will post -2.76 earnings per share for the current fiscal year.

In other news, CEO Kevin Lee sold 1,936 shares of the company’s stock in a transaction dated Monday, July 12th. The shares were sold at an average price of $32.04, for a total transaction of $62,029.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Nigel Crockett sold 72,701 shares of the company’s stock in a transaction dated Tuesday, July 13th. The stock was sold at an average price of $32.44, for a total transaction of $2,358,420.44. Following the transaction, the insider now owns 4,331 shares of the company’s stock, valued at approximately $140,497.64. The disclosure for this sale can be found here. Insiders sold 136,447 shares of company stock worth $4,536,400 over the last ninety days. 17.90% of the stock is currently owned by corporate insiders.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles.

Featured Article: Straddles

Want to see what other hedge funds are holding BCYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bicycle Therapeutics plc (NASDAQ:BCYC).

Institutional Ownership by Quarter for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.